GCM
NKTR icon

Graham Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Graham Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,378
Closed -$106K – 1508
2025
Q1 		$106K Buy
10,378
+3,917
+61% +$51.2K ﹤0.01% 1206
2024
Q4 		$90.1K Buy
6,461
+5,191
+409% +$91.5K ﹤0.01% 1166
2024
Q3 		$24.8K Sell
1,270
-553
-30% -$10.5K ﹤0.01% 1059
2024
Q2 		$33.9K Buy
+1,823
New +$38.4K ﹤0.01% 994
2023
Q3 		– Sell
-1,606
Closed -$13.9K – 1202
2023
Q2 		$13.9K Sell
1,606
-39,387
-96% -$420K ﹤0.01% 930
2023
Q1 		$432K Buy
40,993
+12,200
+42% +$369K 0.01% 780
2022
Q4 		$976K Buy
28,793
+7,169
+33% +$347K 0.03% 542
2022
Q3 		$1.04M Buy
21,624
+4,573
+27% +$272K 0.04% 468
2022
Q2 		$971K Buy
17,051
+9,596
+129% +$605K 0.04% 446
2022
Q1 		$602K Buy
+7,455
New +$1.1M 0.02% 490

Other funds holding NKTR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Graham Capital Management's NKTR Position: Q2 2025 in Review

Graham Capital Management sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 10,378 shares — an estimated $106K sold.

Graham Capital Management first reported a position in NKTR in Q1 2022 and held it in 10 quarters. The position peaked at $1.04M in Q3 2022. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • Graham Capital Management reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Graham Capital Management sold 10,378 Nektar Therapeutics shares in Q2 2025, an estimated $106K.
  • Graham Capital Management first reported a position in Nektar Therapeutics in Q1 2022 and held it in 10 quarters.
  • Graham Capital Management's Nektar Therapeutics position peaked at $1.04M in Q3 2022.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on Graham Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.